Journal of the American Society of Nephrology · 2012 · 171 citations · 32 references
MedicineMolecular BiologyNephrologyRenal PathologyRenal PathophysiologySignal TransductionGlomerular DiseasesGlomerular PathophysiologyPodocyte InjuryRenal DiseaseRenal ImpairmentRenal PhysiologyBowman's CapsuleKidney HistologyMtorc1 SignalingPodocyte BiologyPodocyte DepletionPodocyte FunctionPodocyte HypertrophyProteinuria Reduction
Podocyte depletion leads to glomerulosclerosis, but whether an impaired capacity of podocytes to respond to hypertrophic stress also causes glomerulosclerosis is unknown. We generated transgenic Fischer 344 rats that express a dominant negative AA-4E-BP1 transgene driven by the podocin promoter; a member of the mammalian target of rapamycin complex 1 (mTORC1) pathway, 4E-BP1 modulates cap-dependent translation, which is a key determinant of a cell's hypertrophic response to nutrients and growth factors. AA-4E-BP1 rat podocytes expressed the transgene and had normal kidney histology and protein excretion at 100 g of body weight but developed ESRD by 12 months. Proteinuria and glomerulosclerosis were linearly related to both increasing body weight and transgene dose. Uni-nephrectomy reduced the body weight at which proteinuria first developed by 40%-50%. The initial histologic manifestation of disease was the appearance of bare areas of glomerular basement membrane from the pulling apart of podocyte foot processes, followed by adhesions to the Bowman capsule. Morphometric analysis confirmed the mismatch between glomerular tuft volume and total podocyte volume (number × size) per tuft in relation to weight gain and nephrectomy. Proteinuria and glomerulosclerosis did not develop if dietary calorie restriction prevented weight gain and glomerular enlargement. In summary, failure of podocytes to match glomerular tuft growth in response to growth signaling through the mTORC1 pathway can trigger proteinuria, glomerulosclerosis, and progression to ESRD. Reducing body weight and glomerular growth may be useful adjunctive therapies to slow or prevent progression to ESRD.
32
Regulation of 4E-BP1 phosphorylation: a novel two-step mechanism
Anne‐Claude Gingras, Steven P. Gygi, Brian Raught et al. · Genes & Development · 1999 · 1.3K citations · Full text
Podocyte loss and progressive glomerular injury in type II diabetes.
Maria Enrica Pagtalunan, Paul L. Miller, S Jumping-Eagle et al. · Journal of Clinical Investigation · 1997 · 1.1K citations · Full text
Medicine, Nephrology, Pathology +17
Podocyte Depletion Causes Glomerulosclerosis
Bryan L. Wharram, Meera Goyal, Jocelyn Wiggins et al. · Journal of the American Society of Nephrology · 2005 · 732 citations
Medicine, Nephrology, Pathology +17
Role of mTOR in podocyte function and diabetic nephropathy in humans and mice
Markus Gödel, Björn Hartleben, Nadja Herbach et al. · Journal of Clinical Investigation · 2011 · 543 citations
Medicine, Nephrology, Pathobiology +17